common practice in the care of patients withtype 2 diabetes and can result in enhanced in-sulin secretion and/or peripheral insulin sen-sitivity. However, OADs generally do not 1Amylin Pharmaceuticals, Inc., San Diego, California. 2Eli Lilly and Company, Indianapolis, Indiana.5678_05_p467-477  5/18/05  12:44 PM  Page 467